Introduction {#tca12265-sec-0005}
============

Currently, lung cancer is the most common cancer and the leading cause of cancer death both in China and worldwide.[1](#tca12265-bib-0001){ref-type="ref"}, [2](#tca12265-bib-0002){ref-type="ref"} Non‐small cell lung cancer (NSCLC) accounts for about 85% of lung cancers; lung adenocarcinoma, which accounts for more than 50% of lung cancers, is one of the most common histologic types.[3](#tca12265-bib-0003){ref-type="ref"} In 2011, the International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS) proposed a new international multidisciplinary classification of lung adenocarcinoma.[4](#tca12265-bib-0004){ref-type="ref"} Recently, the Chinese government published a new guideline for primary lung cancer suggesting that the new IASLC/ATS/ERS classification be used as the histologic standard.

According to the IASLC/ATS/ERS classification, the new concepts for adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) are defined. Following comprehensive histologic subtyping, invasive adenocarcinomas are now classified according to the predominant pattern, that is, lepidic (LPA), acinar (APA), papillary (PPA) or solid (SPA); the micropapillary predominant pattern (MPA) has been included as a new histologic subtype with a poor prognosis. The previously termed mucinous bronchioloalveolar carcinomas are now referred to as invasive mucinous adenocarcinoma (IMA).[5](#tca12265-bib-0005){ref-type="ref"}

As the field of lung cancer research is rapidly evolving, particularly in the molecular arena, the importance of molecular pathology is increasing. However, the molecular correlations in lung adenocarcinoma continue to remain unclear. Currently, the only strong molecular correlation for the predominant histologic subtypes of lung adenocarcinoma is v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog (*KRAS*) mutation for IMA.[6](#tca12265-bib-0006){ref-type="ref"}

Information on the prevalence of the clinical characteristics and molecular pathology of the lung adenocarcinoma subtypes as defined by the new IASLC/ATS/ERS classification is still limited. Therefore, we retrospectively analyzed resected specimens of lung adenocarcinoma in Chinese patients in terms of the newly defined histologic subtypes and prevalence of clinical characteristics and molecular pathology.

Materials and methods {#tca12265-sec-0006}
=====================

Specimens {#tca12265-sec-0007}
---------

All 285 resected specimens of primary lung adenocarcinoma (from August 2013 to December 2014) were utilized from the Department of Thoracic Surgery II of the Peking University Cancer Hospital and were confirmed by pathological examination. Sixteen patients who received preoperative chemotherapy or tyrosine kinase inhibitor (TKI) therapy were excluded; therefore, 269 initial patients\' data were analyzed. Epidermal growth factor receptor (EGFR) mutation status in 219 patients and KRAS in 217 patients were examined (others were unknown).

Histological evaluation {#tca12265-sec-0008}
-----------------------

Two pathologists separately evaluated all specimens according to the new classification. Figure [1](#tca12265-fig-0001){ref-type="fig"} depicts the typical histologic component of each subtype. The predominant pattern was defined as the pattern with the largest percentage of carcinoma cells, even when it was \<50%. Staging was in accordance with the standards of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th edition.

![Lung adenocarcinoma histologic subtypes (hematoxylin and eosin stain x40): (**a**) lepidic; (**b**) papillary; (**c**) acinar; (**d**) solid; (**e**) micropapillary; (**f**) mucinous.](TCA-7-017-g001){#tca12265-fig-0001}

Detection of epidermal growth factor receptor (EGFR) and v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations {#tca12265-sec-0009}
------------------------------------------------------------------------------------------------------------------------------

Genomic DNA was extracted from formalin‐fixed paraffin‐embedded (FFPE) samples using a QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany). DNA concentrations were measured by a NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA, USA). Thirty hotspot mutations within exons 18--21 of the *EGFR* gene were examined using a Human EGFR Mutation Qualitative Detection Kit (Beijing ACCB Biotech Ltd, Beijing, China). Hydrolysable fluorescent probes were specifically designed to detect different mutations (point mutations, insertions, and deletions). Seven hotspot mutations in *KRAS* within codons 12 and 13 were detected using a Human KRAS Mutation Qualitative Detection Kit (Beijing ACCB Biotech Ltd). This experiment was performed using an Mx3000P PCR system (Stratagene, La Jolla, CA, USA) according to the manufacturer\'s protocol. The polymerase chain reaction conditions were as follows: initial denaturation at 95°C for 10 minutes, followed by 40 cycles at 95°C for 15 seconds, and 60°C for one minute.

Statistical analysis {#tca12265-sec-0010}
--------------------

The χ^2^ test and Fisher\'s exact test for independence were used to compare the frequencies of the clinicopathologic variables. The Kruskal--Wallis test and logistic regression for independence were used to compare serum carcinoembryonic antigen (CEA) levels in the histologic subtypes. *P* \< 0.05 was considered statistically significant. Statistical analysis was performed with SPSS 19.0 software (IBM Corp., Armonk, NY, USA).

Results {#tca12265-sec-0011}
=======

Clinicopathologic characteristics and histologic features {#tca12265-sec-0012}
---------------------------------------------------------

Table [1](#tca12265-tbl-0001){ref-type="table-wrap"} lists the clinicopathologic characteristics and histologic features of the patients. All specimens were invasive adenocarcinoma: 35 cases were LPA (13.0%), 53 cases were PPA (19.7%), 139 cases were APA (51.7%), 23 cases were SPA (8.6%), three cases were MPA (1.1%), and 16 cases were IMA (5.9%).

###### 

Characteristics of study population

  Factor               Patient number (%)
  -------------------- --------------------
  Gender               
  Female               171 (63.6)
  Male                 98 (36.4)
  Age (years)          
  Range                32∼78
  Mean                 61
  Pathologic stage     
  IA                   123 (45.7)
  IB                   59 (21.9)
  IIA                  43 (16.0)
  IIB                  1 (0.4)
  IIIA                 32 (11.9)
  IIIB                 5 (1.9)
  IV                   6 (2.2)
  Smoking status       
  Former/current       72 (26.8)
  Never                197 (73.2)
  Histologic subtype   
  AIS                  0
  MIA                  0
  LPA                  35 (13.0)
  APA                  139 (51.7)
  PPA                  53 (19.7)
  MPA                  3 (1.1)
  SPA                  23 (8.6)
  IMA                  16 (5.9)
  CA                   0
  FA                   0
  EA                   0
  Total                269

AIS, adenocarcinoma in situ; APA, acinar predominant invasive adenocarcinoma; CA, colloid adenocarcinoma; EA, enteric adenocarcinoma; FA, fetal adenocarcinoma; IMA, invasive mucinous adenocarcinoma; LPA, lepidic predominant invasive adenocarcinoma; MIA, minimally invasive adenocarcinoma; MPA, micropapillary predominant invasive adenocarcinoma; PPA, papillary predominant invasive adenocarcinoma; SPA, solid predominant invasive adenocarcinoma.
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Serum carcinoembryonic antigen levels and lung adenocarcinoma histologic subtypes {#tca12265-sec-0013}
---------------------------------------------------------------------------------

The serum CEA levels of cases were compared among the lung adenocarcinoma histologic subtypes; differences were detected using the Kruskal--Wallis test (*P* = 0.004; Fig [2](#tca12265-fig-0002){ref-type="fig"}). There were significant differences between LPA (*P* = 0.007) and APA (*P* = 0.009) (Table [2](#tca12265-tbl-0002){ref-type="table-wrap"}). In the logistic regression for histologic subtypes including factors of gender, age, CEA level, and pathologic stage, CEA level was significantly associated with LPA (*P* = 0.018, odds ratio = 7.403; 95% confidence interval: 1.414 to 38.769).

![Serum carcinoembryonic antigen (CEA) levels according to lung adenocarcinoma histologic subtype. Lepidic, 2.23 ± 0.20 ng/mL; papillary, 3.44 ± 0.58 ng/mL; acinar, 7.80 ± 2.46 ng/mL; micropapillary predominant pattern, 2.45 ± 0.24 ng/mL; solid, 15.73 ± 9.85 ng/mL; and invasive mucinous adenocarcinoma, 4.28 ± 1.40 ng/mL. *P* = 0.004 (Kruskal--Wallis test). Error bars indicate standard error.](TCA-7-017-g002){#tca12265-fig-0002}

###### 

Correlation between serum CEA level and lung adenocarcinoma histologic subtype

  IASLC/ATS/ERS adenocarcinoma subtype   CEA level (ng/mL)   *P*         
  -------------------------------------- ------------------- ----------- -------
  Lepidic                                                                0.007
  With                                   31                  1 (3.1)     
  Without                                171                 54 (24)     
  Papillary                                                              0.118
  With                                   45                  7 (13.5)    
  Without                                157                 48 (23.4)   
  Acinar                                                                 0.009
  With                                   96                  37 (27.8)   
  Without                                106                 18 (14.5)   
  Solid                                                                  0.779
  With                                   16                  5 (23.8)    
  Without                                186                 50 (21.2)   
  Mucinous                                                               0.321
  With                                   11                  5 (31.3)    
  Without                                191                 50 (20.7)   

ATS, American Thoracic Society; CEA, carcinoembryonic antigen; ERS European Respiratory Society; IASLC, International Association for the Study of Lung Cancer.
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EGFR mutation and clinicopathologic characteristics {#tca12265-sec-0014}
---------------------------------------------------

EGFR mutations were detected in 132 of 219 cases (60.3%). The *EGFR* mutation rate in women was higher than in men, as well as in never‐smokers compared to patients who were smokers. There were no significant differences in the *EGFR* mutation rate in terms of age, serum CEA level, lung membrane invasion, or stage. The *EGFR* mutation rates in the LPA, PPA, APA, SPA, MPA, and IMA were 70.6%, 64.8%, 72.5%, 33.3%, 100%, and 5.9%, respectively. The difference in *EGFR* mutation rates among the subtypes was significant (*P* \< 0.001). *EGFR* mutation was frequently found in the LPA, APA, PPA, and MPA subtypes (Table [3](#tca12265-tbl-0003){ref-type="table-wrap"}). In men and in patients who were smokers, *EGFR* mutation was seldom found in the SPA and IMA subtypes; in women and in patients who were non‐smokers, *EGFR* mutation was seldom found in the IMA subtype (Table [4](#tca12265-tbl-0004){ref-type="table-wrap"}). Exon mutations were divided into two groups: 57 cases (43.2%) with exon 19 mutation and 75 cases (56.8%) with other exon mutations. The distribution of exon mutations differed according to serum CEA level (*P* = 0.018). There were no significant differences in exon mutations according to gender (*P* = 0.568), smoking status (*P* = 0.662) or histologic subtype (*P* = 0.831) (Table [5](#tca12265-tbl-0005){ref-type="table-wrap"}).

###### 

Relationship between *EGFR* mutation and clinicopathologic characteristics

  Factor                   EGFR mutation   *P*   
  ------------------------ --------------- ----- -------
  Gender                                         0.022
  Female                   92 (66.2)       47    
  Male                     40 (50.0)       40    
  Age (years)                                    0.658
  \<65                     88 (59.1)       61    
  ≥65                      44 (62.9)       26    
  Smoking status                                 0.026
  Former/current           26 (47.3)       29    
  Never                    106 (64.6)      58    
  CEA (ng/mL)                                    1.000
  \<5                      84 (60.4)       55    
  ≥5                       48 (60.0)       32    
  Lung membrane invasion                         0.776
  With                     48 (58.5)       34    
  Without                  84 (61.3)       53    
  Stage                                          0.270
  I                        78 (59.1)       54    
  II                       25 (54.3)       21    
  III/IV                   29 (70.7)       12    
  Histologic subtype                             0.000
  LPA                      12 (70.6)       5     
  APA                      83 (64.8)       45    
  PPA                      29 (72.5)       11    
  MPA                      2 (100)         0     
  SPA                      5 (33.3)        10    
  IMA                      1 (5.9)         16    
  Total                    132 (60.3)      87    

APA, acinar predominant invasive adenocarcinoma; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; IMA, invasive mucinous adenocarcinoma; LPA, lepidic predominant invasive adenocarcinoma; MPA, micropapillary predominant invasive adenocarcinoma; PPA, papillary predominant invasive adenocarcinoma; SPA, solid predominant invasive adenocarcinoma.
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###### 

Relationship between EGFR mutation and histologic subtypes

  Histologic subtype   Male   Female     Non‐Smoker   Smoker                                                                                                            
  -------------------- ------ ---------- ------------ -------------------------------------------------- ----- --------------------------------------------------- ---- -----------
  LPA                  5      3 (60)     12           9 (75)                                             15    11 (73.3)                                           2    1 (50)
  APA                  50     27 (54)    78           56 (71.8)                                          94    64 (68.1)                                           6    4 (66.7)
  PPA                  9      7 (77.8)   31           22 (71)                                            34    25 (73.5)                                           34   19 (55.9)
  MPA                  1      1 (100)    1            1 (100)                                            1     1 (100)                                             1    1 (100)
  SPA                  9      1 (11.1)   6            4 (66.7)                                           6     4 (66.7)                                            9    1 (11.1)
  IMA                  6      1 (16.7)   11           0 (0)                                              14    1 (7.1)                                             3    0 (0)
  Total                80     40 (50)    139          92 (66.2)[†](#tca12265-note-0004){ref-type="fn"}   164   106 (64.6)[‡](#tca12265-note-0004){ref-type="fn"}   55   26 (47.3)

†Fisher‐Freeman‐Halton exact test: *P* = 0.018. ‡Fisher‐Freeman‐Halton exact test: *P* = 0.000. APA, acinar predominant invasive adenocarcinoma; EGFR, epidermal growth factor receptor; IMA, invasive mucinous adenocarcinoma; LPA, lepidic predominant invasive adenocarcinoma; MPA, micropapillary predominant invasive adenocarcinoma; PPA, papillary predominant invasive adenocarcinoma; SPA, solid predominant invasive adenocarcinoma.
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###### 

Relationship between *EGFR* exon mutations and clinicopathologic characteristics

  Factor               EGFR mutation   *P*   
  -------------------- --------------- ----- -------
  Gender                                     0.568
  Male                 19              21    
  Female               38              54    
  Smoking status                             0.662
  Former/current       10              16    
  Never                47              59    
  Serum CEA level                            0.018
  \<5                  43              41    
  ≥5                   14              34    
  Histologic subtype                         0.831
  LPA                  6               6     
  APA                  38              45    
  PPA                  11              18    
  SPA                  2               3     
  MPA                  0               2     
  IMA                  0               1     
  Total                57              75    

APA, acinar predominant invasive adenocarcinoma; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; IMA, invasive mucinous adenocarcinoma; LPA, lepidic predominant invasive adenocarcinoma; MPA, micropapillary predominant invasive adenocarcinoma; PPA, papillary predominant invasive adenocarcinoma; SPA, solid predominant invasive adenocarcinoma.
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Relationship between KRAS mutation and lung adenocarcinoma histologic subtype {#tca12265-sec-0015}
-----------------------------------------------------------------------------

KRAS mutations were detected in 20 of 217 cases (9.2%) and were frequently found not only in the IMA subtype, but also in the SPA subtype. There were significant differences in KRAS mutations according to gender (*P* = 0.027), smoking status (*P* = 0.001), and histologic subtype (*P* = 0.006) (Table [6](#tca12265-tbl-0006){ref-type="table-wrap"}).

###### 

Relationship between *KRAS* mutation and lung adenocarcinoma histologic subtype

  Factor               KRAS mutation   *P*   
  -------------------- --------------- ----- -------
  Gender                                     0.027
  Male                 12 (15.4)       66    
  Female               8 (5.8)         131   
  Age (years)                                0.804
  \<65                 13 (8.8)        134   
  ≥65                  7 (10.0)        63    
  Smoking status                             0.001
  Former/current       12 (21.8)       43    
  Never                8 (4.9)         154   
  Serum CEA level                            0.810
  \<5                  12 (8.8)        125   
  ≥5                   8 (10.0)        72    
  Histologic subtype                         0.006
  LPA                  1 (5.9)         16    
  APA                  9 (7.1)         117   
  PPA                  1 (2.5)         39    
  SPA                  3 (20.0)        12    
  IMA                  6 (35.3)        11    
  Total                20 (9.2)        197   

APA, acinar predominant invasive adenocarcinoma; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; IMA, invasive mucinous adenocarcinoma; KRAS, v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog; LPA, lepidic predominant invasive adenocarcinoma; MPA, micropapillary predominant invasive adenocarcinoma; PPA, papillary predominant invasive adenocarcinoma; SPA, solid predominant invasive adenocarcinoma.

2015 China Lung Oncology Group and Wiley Publishing Asia Pty Ltd

Discussion {#tca12265-sec-0016}
==========

Since the IASLC/ATS/ERS classification was published, dozens of published reports have validated various aspects of the classification in resection specimens. However, information on the prevalence of clinical characteristics of lung adenocarcinoma subtypes as defined by the new classification, molecular pathology in particular, remains limited. Thus, we retrospectively analyzed 269 resected cases of initial primary lung adenocarcinoma to identify differences between the histologic subtypes, particularly in terms of *EGFR* mutation.

The most frequent subtype among the resected specimens was APA (52%). Similar results were reported in studies from France (47%), the United States (45%), Korea (41%), and China (40%).[7](#tca12265-bib-0007){ref-type="ref"}, [8](#tca12265-bib-0008){ref-type="ref"}, [9](#tca12265-bib-0009){ref-type="ref"}, [10](#tca12265-bib-0010){ref-type="ref"} In contrast, PPA was the most common subtype reported in Taiwan (35%) and Japan (35%).[11](#tca12265-bib-0011){ref-type="ref"}, [12](#tca12265-bib-0012){ref-type="ref"} This suggests that the most frequent subtype varies according to geographic region or ethnicity.

In NSCLC, serum CEA levels have been widely reported as being correlated with advanced disease, *EGFR* mutation, and survival.[13](#tca12265-bib-0013){ref-type="ref"}, [14](#tca12265-bib-0014){ref-type="ref"}, [15](#tca12265-bib-0015){ref-type="ref"} Our study marks the first time serum CEA levels were compared among lung adenocarcinoma histologic subtypes; differences were detected using the Kruskal--Wallis test (*P* = 0.004). We suspect that the LPA subtype with lower CEA levels might indicate better survival than the APA subtype with higher CEA levels.

Several institutions have reported the percentages of *EGFR* gene mutations in each lung adenocarcinoma histologic subtype. The *EGFR* mutation rates in lung adenocarcinoma differ between Asians and Caucasians.[16](#tca12265-bib-0016){ref-type="ref"} In 138 patients undergoing lung resection in Korea, *EGFR* mutation rates were highest in the MIA subtype (82%), followed by the LPA (74%), APA (53%), AIS (50%), PPA (50%), MPA (50%), SPA (11%), and IMA subtypes (0%).[9](#tca12265-bib-0009){ref-type="ref"} In 320 surgical patients in Japan, *EGFR* mutation rates were highest in the APA subtype (48.9%), followed by the MIA (45%), PPA (43.8%), MPA (40%), LPA (33.3%), IMA (33.3%), AIS (23.8%), and SPA subtypes (17.4%), representing rather high mutation rates for lepidic‐type adenocarcinomas (AIS, MIA, LPA).[12](#tca12265-bib-0012){ref-type="ref"} Another Chinese study (206 cases) reported *EGFR* mutation rates of 80%, 70.7%, 68.8%, 69.5%, 22.5%, and 25% in the MPA, PPA, LPA, APA, SPA, and IMA subtypes, respectively, which were consistent with our results. In our study, the prevalence of *EGFR* gene mutations was highest in the MPA subtype (100%), followed by the PPA (72.5%), LPA (70.6%), APA (64.8%), and SPA subtypes (33.3%), and was lowest in the IMA subtype (5.9%).[10](#tca12265-bib-0010){ref-type="ref"}

Epidermal growth factor receptor mutations are not usually found in the IMA subtype; however, we found an *EGFR* mutation in an IMA subtype.[17](#tca12265-bib-0017){ref-type="ref"} The subtype, as confirmed by the pathologists, showed that the tumor had mixed mucinous and nonmucinous components. We suspect that the mutation was detected from the nonmucinous component.

As tumors with exon 19 deletions are more susceptible to EGFR‐TKI therapy than patients with other exon mutations, such as exon 21 mutation, we divided the 132 *EGFR* mutation cases into two groups: exon 19 mutation (57 cases, 43.2%) and other exon mutations (75 cases, 56.8%).[18](#tca12265-bib-0018){ref-type="ref"}, [19](#tca12265-bib-0019){ref-type="ref"} The distribution of the exon mutations differed according to serum CEA level (*P* = 0.018) but was not related to gender, smoking status or histologic subtype.

Although there are many correlations between histological subtype and EGFR mutations, no histological subtype of lung adenocarcinoma can fully predict EGFR mutation status. Therefore, histological subtypes generally should not be used to guide treatment based on molecular testing in daily clinical practice, and the EGFR mutation test is necessary for any case of lung adenocarcinoma.[5](#tca12265-bib-0005){ref-type="ref"}

When processing small biopsies, there is often not enough tissue for molecular testing or re‐biopsy is difficult to achieve. For these reasons, EGFR mutation status cannot be detected for numbers of patients with advanced lung adenocarcinoma, especially in China, where EGFR mutation rates are quite high. In our study, certain predominant subtypes had quite high EGFR mutation rates. Therefore, we propose that tentative EGFR‐TKI therapy may be acceptable in selected patients.

Multiple reports indicate that *KRAS* mutations are associated with IMA, while others have reported that they are associated with the SPA subtypes.[6](#tca12265-bib-0006){ref-type="ref"}, [17](#tca12265-bib-0017){ref-type="ref"} We believe that *KRAS* mutations are frequently found not only in the mucinous‐predominant subtype, but also in the SPA subtype.

Conclusions {#tca12265-sec-0017}
===========

In China, there are significant differences between lung adenocarcinoma histologic subtypes. The presence of well‐differentiated components in lung adenocarcinoma, such as the lepidic, papillary, and acinar components, indicates higher *EGFR* mutation rates, while the presence of solid or mucinous components indicates higher *KRAS* mutation rates. Additionally, serum CEA levels may be associated with the histologic subtype and *EGFR* exon mutation.
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